Multidrug Resistance in Breast Cancer: From In Vitro Models to Clinical Studies

por Wind, N. S., Holen, I.
Publicado 2011

Benefits of combined treatments using antiresorptive agents and cytotoxic drugs

por Holen, I, Neville-Webbe, H, Coleman, RE
Publicado 2006

Synergistic effects of cytotoxic drugs and antiresorptive agents in vitro and in vivo

por Ottewell, PD, Jones, M, Coleman, RE, Holen, I
Publicado 2006

Effects of combined treatment with Zometa and Taxol on endothelial cells in vitro

por Michailidou, M, Brown, N, Coleman, RE, Holen, I
Publicado 2006

Pretreatment of breast cancer cells with doxorubicin facilitates the subsequent uptake of zoledronic acid

por Lefley, DV, Holen, I, Coleman, RE, Ottewell, PD
Publicado 2008

Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid

por Ottewell, PD, Lefley, DV, Coleman, RE, Holen, I
Publicado 2008

Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction

por Neville-Webbe, H L, Coleman, R E, Holen, I
Publicado 2010

A single administration of combination therapy inhibits breast tumour progression in bone and modifies both osteoblasts and osteoclasts

por Brown, H.K., Ottewell, P.D., Evans, C.A., Coleman, R.E., Holen, I.
Publicado 2012

Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience

por Porter, I., Theodoulou, E., Holen, I., Harper-Wynne, C., Baron-Hay, S., Wilson, C., Brown, J.
Publicado 2021